Clinical trials

#Animal models #Assay development optimisation & technology #Biochemistry #Biomarkers #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Imaging #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Pharmacogenomics #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Systems biology #Toxicology

Surrogate Endpoints In Cancer Trials

Surrogate Endpoints In Cancer Trials By Professor Karol Sikora Over the next 20 years systematic programmes of cancer risk assessment will be established and cancer-preventive drugs will be developed. The ability to prevent cancer will dramatically increase the number of people who will need to regularly attend clinics. This article… Read More

#Archive

#ADME / Tox #Analysis #Automation / robotics #Biomarkers #Business #Cell therapy #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genomics #High throughput screening #Immunology #Lead discovery #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Toxicology

Unrealised wealth in the avalanche of science

Unrealised wealth in the avalanche of science By Dr Benjamin P. Chen The human genome information complemented with high throughput screening, proteomics and molecular structure analysis has significantly increased the speed at which potential drug leads are identified. The Pandora's box of intellectual properties opened as a result is beyond… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Biochemistry #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug targets #Gene therapy #Genetics / genomes #Pathology #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #Target validation #Therapeutics

Stem Cells – The long march forward to the clinic

Stem Cells - The long march forward to the clinic By Dr Alan Colman The area of cellular therapeutics has never been readily embraced by 'Big Pharma', with ethical and regulatory issues even more complex and troublesome than proteins. Can stem cell therapy provide the key to unlocking a rich… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Cell / tissue culture #Cell culture #Cell therapy #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Pharmacogenomics #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Regenerative Medicine – Promising answers in the face of an ageing population

By Dr Doros Platika As the population ages, the scientific and medical communities are working to solve the challenges this changing demographic will place on society. Companies involved in the promising field of regenerative medicine are now on the cutting edge as it strives to promote longevity without disability. Regenerative… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Animal models #Automation / robotics #Business #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Pharmacogenomics #Regulatory #RNA #Screening #Target validation #Toxicology

Biologically Relevant Chemistry

Biologically Relevant Chemistry By Dr Stephen A. Hill A large proportion of R&D expenditure relates to the investigation of compounds which ultimately fail to reach the market as useful medicines. We discuss why early drug discovery - using high throughput, automated in vitro and in silico methods, must become the… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cellular assays #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Protein chemistry / Proteomics #RNA #Screening #Target validation #Therapeutics #Toxicology

Pharmaceutical Industry R&D Partnering Strategies

Pharmaceutical Industry R&D Partnering Strategies By Riccardo Pigliucci Drug Discovery With a sustained rate of more than 250 R&D partnering deals each year many valuable lessons are being learned. Although there is no exact 'formula for success' there are many 'success factors' that can be utilised to reduce the risk… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Business #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Lead discovery #Pharmacology #Pharmokinetics #Preclinical #RNA #Toxicology

e-R&D – The internet at work

e-R&D - The internet at work By Dr Alpheus Bingham and Dr Neil Bodick It is difficult to understand how the continuing growth of large monolithic Research & Development organisations can sustain the industry. With the economies of scale providing diminishing returns we examine the promise of e-R&D and explore… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Business #Clinical specialities #Clinical trials #Drug development #Drug targets #Pharmacology #Regulatory #RNA #System biology

Modelling and simulation in drug development, promise and reality

Modelling and simulation in drug development, promise and reality By Dr Mark Sale Modelling and simulation in drug development is not new. What is new is the vision for moving from a descriptive role (what happened) to a predictive and therefore decision making role. While seemingly attractive, important hurdles, both… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Medicinal chemistry #Microbiology #Molecular medicine #Oncology #Organic chemistry #Pathology #PCR #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

Increasing the chances of lead discovery

Increasing the chances of lead discovery By Sandra Fox, MBA, Dr Helen Wang, Dr Lynne Sopchak and Dr Richard Khoury For HTS laboratories worldwide, the mission is to supply therapeutic groups in the shortest time possible with high quality hits and leads that will become drug candidates. Mounting pressure to… Read More

#Archive

#AI / data analytics / healthtech / informatics #Animal models #Biochemistry #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Immunology #Molecular medicine #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics

The Genie in the Test Tube – From Gene to Gene Therapy: Part 2

The Genie in the Test Tube - From Gene to Gene Therapy: Part 2 By Dr Jan Steiner In the previous edition, we discussed gene therapy in terms of potential vectors and their applications. Now, we discuss the potential clinical uses of these constructs. To date, the main applications of… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Business #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #Immunology #Lead discovery #Molecular medicine #Pharmacogenomics #Protein chemistry / Proteomics #RNA

The promise of pharmacogenetics and pharmacogenomics

The promise of pharmacogenetics and pharmacogenomics By Dr Tim Peakman and Dr Steve Arlington Within the next 10 years the benefits of pharmacogenetics and pharmacogenomics will inevitably outweigh the disadvantages. But what are the commercial and legal implications for the pharmaceutical industry especially for companies who have lead candidates ready… Read More

#Archive

#Analysis #Automation / robotics #Biochemistry #Business #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High throughput screening #Imaging #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Microbiology #Organic chemistry #Protein chemistry / Proteomics #Screening #Stem cells #System biology #Target validation #Toxicology

High-throughput Crystallisation

High-throughput Crystallisation By Dr Sara Moran and Dr Lance Stewart With structure-based drug design on the increase can the development of high-throughput crystallisation fulfil its promise to revolutionise the drug discovery process? In an era when the development of drugs is hindered by the exorbitant costs of discovery and clinical… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development & optimisation #Chemistry #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Microbiology #Molecular medicine #Screening #Sequencing #Stem cells #System biology #Systems biology #Translational #Translational chemistry

The Industrialisation of Bioinformatics

The Industrialisation of Bioinformatics By Dr Alex Titomirov With the completion of the ‘draft’ sequence of the human genome predicting an estimate of 40,000-120,000 genes that describe us, the real work begins. The problem now is not lack of data but lack of tools to thoroughly analyse what we already… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #PCR #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation

Exploiting the fruits of the human genome – A strategic perspective

By Dr David C. U’Prichard It is almost axiomatic that the pharmaceutical R&D industry has not achieved in the last decade an increase in productivity (measured as high value NCEs) commensurate with the explosion of new biological information, chemistry techniques and information storage/retrieval/examination systems, let alone the real increase in… Read More

#Archive

#Academic #Analysis #Analytical chemistry #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Molecular medicine #Oncology #Pharmacogenomics #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Therapeutics #Toxicology

Pharmacogenomics – A new paradigm for drug development

By Michael P. Murphy, MSc Pharmacogenomics offers the opportunity to adopt a new paradigm in drug development. The pharmaceutical industry is faced with a number of challenges including relatively low productivity and success in bringing new drugs to market. Investors demand that pharmaceutical companies deliver several new drugs to the… Read More

#Archive

Genome editing
#AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Cellular & Molecular biology #Clinical trials #Drug development #Drug discovery #Genetics / genomes #Genetics / genomics #Genomics #Lead discovery #Molecular medicine #Preclinical #RNA #Sequencing #System biology #Systems biology #Toxicology

The role of toxicogenomics in drug discovery

The role of toxicogenomics in drug discovery By Dr Robin E. Neft and Dr Spencer Farr The information that toxicogenomics can bring in terms of toxic mechanisms, safety and efficacy must ultimately have a major impact on the drug discovery process. Large scale genome sequencing has lead to elucidation of… Read More

#Archive